<p>明尼蘇達州查斯卡，2026 年 1 月 16 日（全球新聞稿）——Lifecore Biomedical, Inc.（納斯達克：LFCR）（“Lifecore”）是一家全面整合的合同開發和製造組織（“CDMO”），今天宣佈在 2026 年 1 月 14 日，Lifecore 薪酬委員會批准了根據 Lifecore 的股權誘導計劃（經修訂）（“誘導計劃”）授予的限制性股票單位（“RSU”）獎勵，涉及其普通股總計 1,738 股，以及股票期權總計 8,775 股，授予兩名新聘員工。RSU 獎勵和股票期權於 2026 年 1 月 14 日根據 Lifecore 與每位員工之間的聘用信授予，並作為每位員工加入 Lifecore 的重要誘因。</p>
<p>RSU 獎勵和股票期權由 Lifecore 的薪酬委員會批准，並根據誘導計劃作為誘導股權獎勵授予，符合納斯達克上市規則 5635(c)(4)。</p>
<p>RSU 將在授予日期的第三週年時歸屬並結算，前提是持續就業。股票期權的行使價格等於授予日期的公允市場價值（如誘導計劃中定義），並將在授予日期的第一週年時歸屬三分之一的股份，之後每個月歸屬 1/36 的股份，前提是持續就業。股票期權的有效期為七年。RSU 獎勵和股票期權均受獎勵協議和誘導計劃的約束。</p>
<p><strong>關於 Lifecore Biomedical</strong></p>
<p>Lifecore Biomedical, Inc.（納斯達克：LFCR）是一家全面整合的合同開發和製造組織（CDMO），在無菌注射藥物產品的開發、灌裝和封裝方面提供高度差異化的能力，包括複雜配方。作為優質注射級透明質酸的領先製造商，Lifecore 憑藉超過 40 年的專業知識，成為全球和新興生物製藥及生物技術公司的合作伙伴，幫助他們在多個治療類別中將創新推向市場。有關公司的更多信息，請訪問 Lifecore 的網站 www.lifecore.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU56UXdPU00zTXpZMk1qRTRJekl3TURjM05UWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU56UXdPU00zTXpZMk1qRTRJekl3TURjM05UWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDljZDcxYTctZThhMS00NDI5LTg2OGItMjFiNjE2NzNlY2EyLTEwMTkzMjktMjAyNi0wMS0xNi1lbg==/tiny/Lifecore-Biomedical-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDljZDcxYTctZThhMS00NDI5LTg2OGItMjFiNjE2NzNlY2EyLTEwMTkzMjktMjAyNi0wMS0xNi1lbg==/tiny/Lifecore-Biomedical-Inc-.png"/></p>
<pre><code>Lifecore Biomedical, Inc. 聯繫信息：Stephanie Diaz（投資者）Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons（媒體）Vida Strategic Partners 415-675-7402 tbrons@vidasp.com Ryan D. Lake（首席財務官）Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
</code></pre>

LFCR

<p>Lifecore Biomedical, Inc. 宣佈根據納斯達克上市規則 5635(c)(4) 批准對兩名新聘員工的激勵授予。授予包括 1,738 股限制性股票單位（RSUs）和 8,775 股股票期權，生效日期為 2026 年 1 月 14 日。限制性股票單位將在授予三週年時歸屬，而股票期權將在七年內逐步歸屬。Lifecore 是一家專注於無菌注射藥品的合同開發和製造組織</p>

<p>CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.</p>
<div class="lb-trans"><p>明尼蘇達州查斯卡，2026 年 1 月 16 日（全球新聞稿）——Lifecore Biomedical, Inc.（納斯達克：LFCR）（“Lifecore”）是一家全面整合的合同開發和製造組織（“CDMO”），今天宣佈在 2026 年 1 月 14 日，Lifecore 薪酬委員會批准了根據 Lifecore 的股權誘導計劃（經修訂）（“誘導計劃”）授予的限制性股票單位（“RSU”）獎勵，涉及其普通股總計 1,738 股，以及股票期權總計 8,775 股，授予兩名新聘員工。RSU 獎勵和股票期權於 2026 年 1 月 14 日根據 Lifecore 與每位員工之間的聘用信授予，並作為每位員工加入 Lifecore 的重要誘因。</p>
</div><p>The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.</p>
<div class="lb-trans"><p>RSU 獎勵和股票期權由 Lifecore 的薪酬委員會批准，並根據誘導計劃作為誘導股權獎勵授予，符合納斯達克上市規則 5635(c)(4)。</p>
</div><p>The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.</p>
<div class="lb-trans"><p>RSU 將在授予日期的第三週年時歸屬並結算，前提是持續就業。股票期權的行使價格等於授予日期的公允市場價值（如誘導計劃中定義），並將在授予日期的第一週年時歸屬三分之一的股份，之後每個月歸屬 1/36 的股份，前提是持續就業。股票期權的有效期為七年。RSU 獎勵和股票期權均受獎勵協議和誘導計劃的約束。</p>
</div><p><strong>About Lifecore Biomedical</strong></p>
<div class="lb-trans"><p><strong>關於 Lifecore Biomedical</strong></p>
</div><p>Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.</p>
<div class="lb-trans"><p>Lifecore Biomedical, Inc.（納斯達克：LFCR）是一家全面整合的合同開發和製造組織（CDMO），在無菌注射藥物產品的開發、灌裝和封裝方面提供高度差異化的能力，包括複雜配方。作為優質注射級透明質酸的領先製造商，Lifecore 憑藉超過 40 年的專業知識，成為全球和新興生物製藥及生物技術公司的合作伙伴，幫助他們在多個治療類別中將創新推向市場。有關公司的更多信息，請訪問 Lifecore 的網站 www.lifecore.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU56UXdPU00zTXpZMk1qRTRJekl3TURjM05UWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNzQwOSM3MzY2MjE4IzIwMDc3NTY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDljZDcxYTctZThhMS00NDI5LTg2OGItMjFiNjE2NzNlY2EyLTEwMTkzMjktMjAyNi0wMS0xNi1lbg==/tiny/Lifecore-Biomedical-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZDljZDcxYTctZThhMS00NDI5LTg2OGItMjFiNjE2NzNlY2EyLTEwMTkzMjktMjAyNi0wMS0xNi1lbg==/tiny/Lifecore-Biomedical-Inc-.png"/></p>
<pre><code>Lifecore Biomedical, Inc. Contact Information:Stephanie Diaz (Investors)Vida Strategic Partners415-675-7401sdiaz@vidasp.comTim Brons (Media)Vida Strategic Partners415-675-7402tbrons@vidasp.comRyan D. Lake (CFO)Lifecore Biomedical952-368-6244ryan.lake@lifecore.com
</code></pre>
<div class="lb-trans"><pre><code>Lifecore Biomedical, Inc. 聯繫信息：Stephanie Diaz（投資者）Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons（媒體）Vida Strategic Partners 415-675-7402 tbrons@vidasp.com Ryan D. Lake（首席財務官）Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
</code></pre>
</div>

Lifecore 宣佈根據納斯達克上市規則 5635(c)(4) 授予誘導性股票獎勵 | NBI 股票新聞